ClearPoint Neuro, Inc.
CLPTNasdaq
$15.15
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +33.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$447.6M
Enterprise Value
$461.7M
P/E
—
P/S
11.0
P/B
23.8
EV/EBITDA
—
PEG
—
FCF Yield
-6.0%
Dividend Yield
—
Revenue (TTM)
$40.6M
Net Income (TTM)
-$29.1M
Free Cash Flow (TTM)
-$26.7M
Gross Margin
62.3%
Operating Margin
-65.2%
Net Margin
-71.6%
ROE
-154.3%
ROIC
-63.6%
Debt / Equity
2.6
Net Cash
-$14.1M
Return 1Y
+33.1%
Company profile
ClearPoint Neuro, Inc. develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. ClearPoint system for insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain.
- CEO
- Joseph M. Burnett
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 110
- Headquarters
- California
- Website
- clearpointneuro.com
Management & directors
- Burnett Joseph MichaelCEO and President
- D'Alessandro DaniloChief Financial Officer
- Stigall L. JeremyChief Business Officer
- Sabra MazinChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
CLPT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$12.1M↑ +42.9%
Diluted EPS-$0.32↑ +45.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $12.8M | $16.3M | $20.6M | $24.0M | $31.4M | $37.0M |
| Gross profit | $9.1M | $11.1M | $13.5M | $13.6M | $19.1M | $22.7M |
| Operating income | -$6.2M | -$13.4M | -$16.3M | -$22.4M | -$19.7M | -$24.2M |
| Net income | -$6.8M | -$14.4M | -$16.4M | -$22.1M | -$18.9M | -$25.5M |
| Diluted EPS | — | -$0.69 | -$0.68 | -$0.90 | -$0.70 | -$0.90 |
| Operating cash flow | -$7.8M | -$12.7M | -$16.2M | -$13.7M | -$8.9M | -$23.9M |
| Free cash flow | -$7.8M | -$12.9M | -$16.4M | -$14.4M | -$9.2M | -$24.4M |
| Gross margin | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating margin | -48.5% | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Net margin | -52.9% | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.9M | $8.1M | $7.8M | $8.5M | $9.2M | $8.9M | $10.4M | $12.1M |
| Gross profit | $5.0M | $4.8M | $4.8M | $5.1M | $5.6M | $5.6M | $6.4M | $7.8M |
| Operating income | -$4.7M | -$5.2M | -$5.6M | -$6.2M | -$5.7M | -$5.3M | -$7.0M | -$8.5M |
| Net income | -$4.4M | -$5.0M | -$5.4M | -$6.0M | -$5.8M | -$5.9M | -$7.8M | -$9.6M |
| Diluted EPS | -$0.16 | -$0.18 | -$0.20 | -$0.22 | -$0.21 | -$0.21 | -$0.26 | -$0.32 |
| Operating cash flow | -$2.7M | -$1.2M | -$1.2M | -$6.2M | -$2.6M | -$3.1M | -$12.1M | -$8.0M |
| Free cash flow | -$2.7M | -$1.2M | -$1.5M | -$6.4M | -$2.6M | -$3.3M | -$12.1M | -$8.6M |
| Gross margin | 63.5% | 59.7% | 61.3% | 60.5% | 60.3% | 63.2% | 61.5% | 64.0% |
| Operating margin | -60.1% | -63.5% | -72.5% | -72.6% | -61.6% | -59.5% | -67.7% | -69.9% |
| Net margin | -56.1% | -61.2% | -69.3% | -71.0% | -63.3% | -66.5% | -74.8% | -78.8% |
Company news
Jun 18, 2026
May 27, 2026
- 54d agoClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprintfinance.yahoo.com
- 54d agoHow The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risksfinance.yahoo.com
May 13, 2026
- 67d agoClearPoint Neuro Q1 Earnings Call Highlightsmarketbeat.com
- 67d agoCompared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metricsfinance.yahoo.com
- 67d agoClearPoint Neuro Q1 2026 Earnings Call Transcriptfinance.yahoo.com
- 67d agoClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com
- 68d agoClearPoint Neuro Reports First Quarter 2026 Resultsfinance.yahoo.com
- 68d agoClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprintfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | FLETCHER R JOHN | Award | 662 | $17.84 | $11,810.08 | filing |
| 2026-07-01 | Richards Timothy T. | Award | 222 | $17.84 | $3,960.48 | filing |
| 2026-06-30 | STIGALL L. JEREMY· Chief Business Officer | Award | 1,781 | $11.93 | $21,247.33 | filing |
| 2026-06-30 | BURNETT JOSEPH MICHAEL· CEO and President | Award | 1,361 | $11.93 | $16,236.73 | filing |
| 2026-06-30 | D'Alessandro Danilo· Chief Financial Officer | Award | 1,085 | $11.93 | $12,944.05 | filing |
| 2026-06-29 | BURNETT JOSEPH MICHAEL· CEO and President | Sale | 20,000 | $19.38 | $387,600.00 | filing |
| 2026-06-29 | BURNETT JOSEPH MICHAEL· CEO and President | Option exercise | 20,000 | $2.50 | $50,000.00 | filing |
| 2026-06-17 | BURNETT JOSEPH MICHAEL· CEO and President | Sale | 60,000 | $17.79 | $1.1M | filing |
| 2026-06-17 | BURNETT JOSEPH MICHAEL· CEO and President | Option exercise | 60,000 | $2.50 | $150,000.00 | filing |
| 2026-06-17 | BURNETT JOSEPH MICHAEL· CEO and President | Sale | 1,843 | $17.94 | $33,063.42 | filing |
| 2026-06-04 | Richards Timothy T. | Tax withholding | 376 | $13.30 | $5,000.80 | filing |
| 2026-06-04 | Richards Timothy T. | Option exercise | 500 | $10.00 | $5,000.00 | filing |
| 2026-06-01 | Richards Timothy T. | Sale | 5,415 | $12.17 | $65,900.55 | filing |
| 2026-05-21 | Klein Matthew B. | Sale | 16,000 | $11.59 | $185,440.00 | filing |
| 2026-05-20 | FALLON LYNNETTE C | Sale | 5,091 | $11.14 | $56,713.74 | filing |
| 2026-05-19 | Klein Matthew B. | Option exercise | 12,417 | — | — | filing |
| 2026-05-19 | FALLON LYNNETTE C | Option exercise | 12,417 | — | — | filing |
| 2026-05-19 | FLETCHER R JOHN | Option exercise | 12,417 | — | — | filing |
| 2026-05-19 | Richards Timothy T. | Option exercise | 12,417 | — | — | filing |
| 2026-05-19 | JOHNSON B KRISTINE | Option exercise | 12,417 | — | — | filing |
| 2026-05-19 | Girin Pascal E R | Option exercise | 12,417 | — | — | filing |
| 2026-05-19 | LIAU LINDA M. | Option exercise | 12,417 | — | — | filing |
| 2026-04-01 | FLETCHER R JOHN | Award | 1,270 | $9.10 | $11,557.00 | filing |
| 2026-04-01 | Girin Pascal E R | Award | 755 | $9.10 | $6,870.50 | filing |
| 2026-04-01 | Richards Timothy T. | Award | 442 | $9.10 | $4,022.20 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.